ATE395906T1 - Träger in partikelform zur verbesserung der oral- absorption von wikstoffen - Google Patents

Träger in partikelform zur verbesserung der oral- absorption von wikstoffen

Info

Publication number
ATE395906T1
ATE395906T1 AT01984141T AT01984141T ATE395906T1 AT E395906 T1 ATE395906 T1 AT E395906T1 AT 01984141 T AT01984141 T AT 01984141T AT 01984141 T AT01984141 T AT 01984141T AT E395906 T1 ATE395906 T1 AT E395906T1
Authority
AT
Austria
Prior art keywords
improve
oral absorption
drugs
carrier
particle form
Prior art date
Application number
AT01984141T
Other languages
English (en)
Inventor
Philippe Maincent
Nathalie Ubrich
Claude Vigneron
Original Assignee
Rovi Lab Farmaceut Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rovi Lab Farmaceut Sa filed Critical Rovi Lab Farmaceut Sa
Application granted granted Critical
Publication of ATE395906T1 publication Critical patent/ATE395906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT01984141T 2000-07-07 2001-07-05 Träger in partikelform zur verbesserung der oral- absorption von wikstoffen ATE395906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0008902A FR2811227A1 (fr) 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs

Publications (1)

Publication Number Publication Date
ATE395906T1 true ATE395906T1 (de) 2008-06-15

Family

ID=8852251

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01984141T ATE395906T1 (de) 2000-07-07 2001-07-05 Träger in partikelform zur verbesserung der oral- absorption von wikstoffen

Country Status (17)

Country Link
US (1) US8052998B2 (de)
EP (1) EP1313453B1 (de)
JP (1) JP5175017B2 (de)
KR (1) KR20030038655A (de)
CN (1) CN1440277A (de)
AT (1) ATE395906T1 (de)
AU (1) AU2002218745A1 (de)
BR (1) BRPI0112080B1 (de)
CA (1) CA2415414C (de)
DE (1) DE60134147D1 (de)
DK (1) DK1313453T3 (de)
ES (1) ES2305121T3 (de)
FR (1) FR2811227A1 (de)
MX (1) MXPA03000193A (de)
PT (1) PT1313453E (de)
RU (1) RU2003103596A (de)
WO (1) WO2002003960A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060253A1 (de) * 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmazeutische Formen zur Freisetzung von Wirkstoffen
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
EP1615632B1 (de) * 2003-04-17 2006-12-06 Jallal Messadek Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
CA2596011C (en) * 2005-02-17 2013-05-14 Medivas, Llc Polymer particle delivery compositions and methods of use
RU2007143510A (ru) * 2005-04-27 2009-06-10 Яллал МЕССАДЕК (BE) Инсулиновые композиции
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP2213282A1 (de) * 2009-01-30 2010-08-04 Laboratorios Farmaceuticos Rovi, S.A. Pharmazeutische Formen zur Freisetzung von Wirkstoffen
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
EP2240162A4 (de) * 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9101547B2 (en) * 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
DE102012019029A1 (de) 2012-09-27 2014-03-27 Alf Lamprecht Arzneiformulierungen zur oralen Gabe von therapeutischen Substanzen und Verfahren zur Herstellung
US10398655B2 (en) 2016-02-18 2019-09-03 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
KR100259989B1 (ko) * 1991-10-01 2000-08-01 모리다 가쓰라 서방성 마이크로캡슐 제제 및 그의 제조법
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6346274B1 (en) * 1995-03-10 2002-02-12 Roche Diagnostics Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
FR2769853B1 (fr) * 1997-10-21 2000-01-28 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU3471400A (en) * 1999-01-19 2000-08-07 Children's Hospital Of Philadelphia, The Compositions and methods for controlled delivery of virus vectors

Also Published As

Publication number Publication date
PT1313453E (pt) 2008-07-16
DE60134147D1 (de) 2008-07-03
CA2415414C (fr) 2011-08-23
WO2002003960A1 (fr) 2002-01-17
FR2811227A1 (fr) 2002-01-11
AU2002218745A1 (en) 2002-01-21
BR0112080A (pt) 2003-05-06
EP1313453B1 (de) 2008-05-21
CN1440277A (zh) 2003-09-03
MXPA03000193A (es) 2004-09-13
BRPI0112080B1 (pt) 2017-01-24
KR20030038655A (ko) 2003-05-16
US8052998B2 (en) 2011-11-08
RU2003103596A (ru) 2004-08-20
US20050013866A1 (en) 2005-01-20
ES2305121T3 (es) 2008-11-01
EP1313453A1 (de) 2003-05-28
DK1313453T3 (da) 2008-09-22
JP2004502720A (ja) 2004-01-29
CA2415414A1 (fr) 2002-01-17
JP5175017B2 (ja) 2013-04-03

Similar Documents

Publication Publication Date Title
DE60134147D1 (de) Träger in partikelform zur verbesserung der oral- absorption von wikstoffen
EP1374908A3 (de) Polymere-Arzneimittel Konjugate die eine Hydrazidolinkergruppe enthalten
MXPA03011935A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
NO20013883L (no) Frysetörket middel inneholdende paramylon, samt fremstilling og anvendelse derav
MA25688A1 (fr) 2-thio-3, 5-dicyano-4-aryl-6-aminopyridines substituees et leur utilisation.
MY129356A (en) Electrospun pharmaceutical compositions
DE60327693D1 (de) Topische zusammensetzung enthaltend ein cyclofructan, einen träger und einen arzneistoff
DE60208177D1 (de) Propylenpolymerzusammensetzung, formkörper und polyolefincopolymer
DE60035127D1 (de) Mit polysacchariden beschichtete träger, deren herstellung und verwendung
BR0317682A (pt) Composição farmacêutica de liberação modificada
TR199801480A3 (tr) Toz halinde, karsilikli birlesebilen tekstil baglayici birlesim.
ID21305A (id) Turunan imidazolidin tersubstitusi, pembuatannya, penggunaannya dan sediaan farmasi yang mengandung bahan yang sama
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DE60139195D1 (de) Aktivierbare polymerzusammensetzung, und gegenstände, die diese nutzen
TR200503846T2 (tr) Değiştirilmiş salimli ensülin sensitizörü için fterkip ve kullanımı
ID26611A (id) Turunan-turunan pirol tersubstitusi heteroaril, pembuatannya dan kegunaan-kegunaan terapetiknya
AR017436A1 (es) Una composicion farmaceutica en una dispersion molecular con biodisponibilidad mejorada
DE60136367D1 (de) Pharmazeutische zusammensetzung mit modifiziertem träger
FR2807321B1 (fr) Nouvel actif, composition le renfermant et utilisation en cosmetique, dermocosmetique, dermopharmacie ou pharmacie ou sur des supports tisses ou non tisses
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
ATE219665T1 (de) Dosisformen und deren verwendungen
NL193406B (nl) Kunstmest met een hoge hardheid en opslagstabiliteit, alsmede de bereiding hiervan.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313453

Country of ref document: EP